Pazopanib, a PDGFR/ vascular endothelial growth factor receptor (VEGFR)/ c-kit (stem cell factor receptor) inhibitor [13], is the only tyrosine kinase inhibitor approved for advanced soft tissue sarcomas in Japan. This evidence concerns the gene PDGFRB and soft tissue sarcoma.